Navigation Links
New Phase 3 Study of Tapentadol Immediate Release Tablets Published in Current Medical Research and Opinion Journal
Date:5/26/2009

SPID(24), SPID(72)).

Treatment with 50-mg or 75-mg of tapentadol IR resulted in 77.5 percent and 76 percent of patients, respectively, experiencing at least a 30 percent improvement in pain intensity at 48 hours. This is comparable to the 75 percent of patients who experienced the same percentage of improvement with 10-mg of oxycodone IR. Results were similar for patients who experienced a 50 percent improvement in pain intensity at 48 hours: 65 percent in the tapentadol IR 50-mg group, 64 percent in the tapentadol IR 75-mg group and 64 percent in the oxycodone IR 10-mg group.

The most common treatment-emergent adverse events in all active treatment groups included nausea, vomiting, dizziness, headache, somnolence (drowsiness) and constipation. Compared to oxycodone IR, the incidence of nausea and/or vomiting was significantly lower with tapentadol IR 50-mg: 35 percent compared to 59 percent respectively (P <0.001). In addition, the percentage of patients who experienced nausea and/or vomiting in the tapentadol IR 75-mg group was slightly lower than the oxycodone 10-mg group: 51 percent versus 59 percent (P=0.057).

"We are encouraged by this Phase 3 study because it shows that patients treated with tapentadol IR experienced effective analgesic relief of moderate to severe acute pain with fewer incidences of nausea and/or vomiting compared with a comparable dose of oxycodone IR, a standard pain treatment," said lead study author David Upmalis, M.D., Senior Director, J&JPRD. "Side effects are an important consideration in pain management. If healthcare professionals have a treatment option that offers the possibility for fewer side effects, it could lead to better patient outcomes."

On November 20, 2008, the FDA approved tapentadol immediate release tablets for the relief of moderate to severe acute pain in patients 18 years of age or older. Tapentadol IR tablets have been approved
'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dainippon Sumitomo Pharma Announces Lurasidone Phase III Data in Patients With Schizophrenia
2. Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
3. Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
4. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
5. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. Pixantrone Phase 3 Data to be Presented at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting
8. Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009
9. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
10. Medarex Announces Primary Endpoint Achieved in MDX-1100 Anti-IP-10 Antibody Phase 2 Trial for Rheumatoid Arthritis
11. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... India , September 3, 2015 ... Metallic compounds, Organosulfurs, Organic acids, Phenolics, and Others) and ... & beverage, Paints & coatings, and Others) - Global ... and segments the Biocides Market with an analysis and ... as value. Browse   88 tables ...
(Date:9/3/2015)... and REHOVOT, Israel, Sept. 3, 2015 ... and developing innovative therapies for ear, nose, and throat ... Company,s Newport Gateway office complex to be the location ... the move by end of September and will have ... U.S. Headquarters: OticPharma, Inc. 19900 MacArthur Blvd., ...
(Date:9/2/2015)... , Sept. 2, 2015 Balloon angioplasty ... obstructed blood vessels. This report is on global ... of the market. The report comprises an elaborate ... provides overall information of various segments and sub-segments ... the overall information and data analysis of the ...
Breaking Medicine Technology:Biocides Market Worth 10.6 Billion USD by 2020 2Biocides Market Worth 10.6 Billion USD by 2020 3Biocides Market Worth 10.6 Billion USD by 2020 4Biocides Market Worth 10.6 Billion USD by 2020 5OticPharma Establishes U.S. Headquarters in Orange County, California 2Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Angioplasty Balloons Market: : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3
(Date:9/3/2015)... ... September 03, 2015 , ... ... providers, has been retained to lead a national chief executive officer ... search firms in the healthcare industry, B. E. Smith has recently placed more ...
(Date:9/3/2015)... ... September 03, 2015 , ... Dr. Robert Winchell has been appointed director ... Acute Care at NewYork-Presbyterian/Weill Cornell Medical Center, effective July 27. He will serve on ... expert in care for the critically injured and the development, design and operations of ...
(Date:9/3/2015)... ... September 03, 2015 , ... According to an Oncology ... test that may help patients with oropharyngeal cancer (oral cancer) to be successfully diagnosed ... are often caused by HPV infections, which have a high rate of success in ...
(Date:9/3/2015)... ... September 03, 2015 , ... Global Vision , the ... will be spotlighting its award-winning print and artwork inspection solutions, ScanProof and ... and 17 at the Olympia London, booth #F33 , Be the first to get ...
(Date:9/3/2015)... (PRWEB) , ... September 03, 2015 , ... ... Act (ACA) triggering cost increases for fully insured employer-sponsored health insurance plans, more ... employers (1,000+ employees), according to data released from the 2014 United Benefit Advisors ...
Breaking Medicine News(10 mins):Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Melissa Memorial Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 2Health News:LA Periodontists Discuss Study on Post-Treatment Oral Rinses Used to Test Recurrence of Oral Cancers 3Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 2Health News:Global Vision to Spotlight Intelligent Proofreading at Packaging Innovations 2015 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 2Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 3Health News:Self-Funded Pharmacy Plans Becoming More Popular Among Large Employers 4
... The experts reveal that lot more funds are needed from ... deaths of children under five by two-thirds.// ,Five ... experts, whose paper is one of the series of papers ... high-level meeting hosted by the journal, UNICEF and the Norwegian ...
... drug extensively used to treat acne can cause depression. ... animals.// ,Recently, the drug- Roaccutane, which effectively ... severe side-effects like suicidal behaviour. Though the packaging of ... occurrence of such side-effects is not known.,It has not ...
... an anti-cancer drug called Biomab-EGFR and had Shah Rukh Khan ... told reporters that the drug would be priced at 40 ... "Today we join the exclusive league of MAb developers worldwide. ... she added. She also told the drug was undergoing regulatory ...
... and Kashmir has a new problem to contend with now ... there are 745 such cases in the insurgency-hit state, unofficial ... there were only two cases reported, writes Grassroots Features. The ... the infection rate among the high-risk groups (STD-infected) at 0.95 ...
... arm in a motorcycle accident. She has become the first woman to ... own nerves. ,She talked about how she used it ... able to eat in a conventional way since her accident of over ... me.” ,Very often patients fitted with high-tech prosthetic limbs ...
... A new web site at the University of California, ... will enable people from around the world// to self-report ... other cholesterol drugs. ,“This line of research ... heart disease and cholesterol are familiar with the benefits ...
Cached Medicine News:Health News:Child death reduction needs five times more funds 2Health News:Acne drug may cause depression 2Health News:Kashmir Grapples with Growing AIDS 2Health News:Kashmir Grapples with Growing AIDS 3Health News:Bionic Women –No longer the Stuff of Science Fictio 2Health News:Patients Can Report Statins' Adverse Effects on New Web Site 2
... Coagulation tubes contain a buffered ... available with a citrate concentration ... 0.129 mol/l (3.8%). The mixing ... solution to 9 parts blood. ...
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
Inquire...
... as either EDTA K2 or EDTA ... ions and therefore blocks the coagulation ... an EDTA anticoagulated blood sample are ... EDTA tubes are for the examination ...
Medicine Products: